Toronto, Ontario and Tel Aviv, Israel–(Newsfile Corp. – May 12, 2023) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC (“Litchfield”) to
Toronto, Ontario and Tel Aviv, Israel–(Newsfile Corp. – May 8, 2023) – NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone“), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive stock options (“Options“) and
NurExone’s research and development investment grew by 143.9% from US$0.57 million in 2021 to US$1.39 million in 2022, due to increased activity in preclinical trials in the Company’s labs. The Company recently disclosed additional results from an internal preclinical study of its investigational drug, ExoPTEN, which demonstrated effective treatment of 75%
The Company’s most recent preclinical trials, that have taken place over 10 weeks in NurExone’s labs in Israel, have proven that its experimental drug ExoPTEN caused 75% of rat subjects in the study to regain hind limb reflex, some motor function, and sensory control. These rats, who regained function, also
The current study was designed to assess the impact of ExoPTEN on the motor, reflex, and sensory recovery of rats, following full transection (i.e. complete severing) of the spinal cord. Read More >>>
NurExone has established itself as a unique company by possessing both a product in development, ExoPTEN, and an advanced platform for the production and loading of exosomes. This combination aims to position the company ahead of its competitors in terms of effectiveness and efficiency. Read More >>>
The Patent discloses and claims groundbreaking inventions and methods in exosome technology, such as the pharmaceutical compositions comprising extracellular vesicles including exosomes, loaded with an exogenous inhibitor of phosphatase and tensin homolog (PTEN) inhibitor as well as a method for treating neuronal injury or damage, including intranasal administration. Read More
It has been an outstanding year with significant scientific and business developments! We move forward to a greater achievements and accomplishments! Read More …
We started our journey to provide much-needed therapy for people who have suffered spinal cord injuries and have accomplished very significant achievements in 2022. As we progress with developing our underlying technology, the awareness of a greater picture has intensified. The same technologies and science that will serve NurExone may
The Company agreed to settle debts in the aggregate amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at the market price on November 24, 2022 of CAD$0.38 per share. These debts were incurred prior to the recent Reverse Takeover Transaction following which NurExone began trading
